RAC-GS$^{Q\&As}$

Regulatory Affairs Certification (RAC) Global Scope

Pass RAPS RAC-GS Exam with 100% Guarantee

Free Download Real Questions & Answers **PDF** and **VCE** file from:

https://www.geekcert.com/rac-gs.html

100% Passing Guarantee
100% Money Back Assurance

Following Questions and Answers are all new published by RAPS Official Exam Center

QUESTION 1

The intermediate manufacturing process was changed during development of a pharmaceutical. The change may impact the API specification. Which functional area is responsible for the final approval of the change?

A. Production

B. Analytical

C. Quality

D. Regulatory

Correct Answer: CD

QUESTION 2

One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority\\'s request?

A. "Given the advisory committee\\'s unanimous decision, we know that the product will not be approved, and additional data will not make any difference."

B. "We have no additional informationto provide at this time, but wecan perform an additional analysis for a specific safety concern, if necessary."

C. "We disagree with the advisory committee\\'s decision because the committee neglected the thorough safety analysis that we provided."

D. "We have no additional information to provide at this time because we have already provided everything needed to support our product\\'s approval."

Correct Answer: B

QUESTION 3

As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?

A. Inform the regulatory authorities.

B. Delay the start of product production.

C. Correct the label text.

D. Abort the product launch.

Correct Answer: A

QUESTION 4

Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?

A. Utilize the STED template to complete global requirements.

B. Initiate a global submission process after all submission data are finalized.

C. Identify countries where special requirements exist during the product development phase.

D. Plan regulatory approval update meetings with senior management and stakeholders.

Correct Answer: C

QUESTION 5

Which of the following statements regarding the off-label use of drugs is CORRECT?

A. Although the regulatory authority reviews and approves drugs for specific indications, theapproval does not limit the use of those drugs in clinical practice.

B. The regulatory authority does not restrict physician prescribing for off-label indications orregulate the manufacturer\\'s promotion for such use.

C. Sponsors are allowed to distribute publications about unapproved uses of approved drugs and devices as long as the marketing application is under review by the regulatory authority.

D. The peer-reviewed literature can ensure high-quality off-label promotion of medications, thereby increasing accessto much needed drugs and devices.

Correct Answer: A